Penn Medicine to Conduct New Clinical Trial to Evaluate Safety and Efficacy of Chewing Gum Designed by School of Dental Medicine Researchers to Trap SARS-CoV-2 in Saliva
The trial will recruit participants from a pool of Penn Medicine employees whose responses to the PennOpen Pass screening system indicate that they may be infected with COVID-19.
Their innovative work was recognized by the Philadelphia Business Journal's PHL Inno initiative, which awards people 25 years and younger who are making an impact in the area’s startup ecosystem.
This year, the University of Pennsylvania ranked particularly high in the research category, coming in at number two, second only to Massachusetts Institute of Technology (MIT).
Penn Spinout Interius BioTherapeutics Is Developing Tools to Perform Cell and Gene Engineering Directly in the Human Body
The hope is that this new technology could simplify the process of CAR-T cell therapy and make gene therapy widely available as a one-time injection to a much larger number of patients.
The University of Pennsylvania (Penn) Telehealth Research Center in Cancer Care (Penn TRACE) will become one of four NCI Telehealth Research Centers of Excellence.
The Penn Institute for RNA Innovation is a new institute dedicated to the understanding and development of all aspects of RNA from basic to translational science.
PCI Startup SchoolSims Named One of the 100 Fastest Growing Companies in the Philadelphia Region by Philadelphia100® Forum
SchoolSims is an education company that offers technology-enhanced immersive learning solutions to leadership development for educational and other organizations.
Penn Health-Tech is well known for turning innovative ideas across the health system into useful technologies and products that solve problems and advance health care.
Penn Spinout Verismo Therapeutics Announces Submission of Investigational New Drug Application to the FDA for KIR-CAR T-cell Immunotherapy Candidate
Pending regulatory approval, Verismo plans to use the drug in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.
Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate
iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.